Ouch.
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1
Large RCT finds no survival benefit for remdesivir, lopinavir, hydroxychloroquine, or interferon beta.
The lopinavir and HCQ results are no surprise. Both have a steady track record of failure in randomized trials. The remedsivir results are disappointing, and this trial is much larger than the ACTT trial on which the drug’s EUA was based. The interferon result is disappointing.
This trial was not designed to limit treatment to pts with early or late stage disease, or other pt subgroups. So it might not detect efficacy if a drug is only beneficial in a subgroup, or if a drug is beneficial in some subgroups but harmful in others.
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1